Radiolabeled MGL Ligands for PET Enzyme Occupancy Imaging

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for positron emission tomography (PET) radiotracers to evaluate monoacylglycerol lipase (MGL) expression, distribution, and occupancy by its inhibitors, which are critical for research and development of therapeutic candidates targeting MGL.

Innovation Solution

Development of a novel compound with monoacylglycerol lipase affinity, containing a positron-emitting radioligand, for use in PET imaging to assess MGL receptor expression, distribution, and enzyme occupancy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Difficulty of detecting and measuring

If a PET radiotracer is developed to evaluate MGL expression and distribution, then non-invasive imaging capability is improved, but the complexity of radioligand synthesis and handling increases

Engineering Contradiction:

ImproveMGL expression and distribution detectionVSAvoidradioligand synthesis and handling

Core Design Contradiction:

Difficulty of detecting and measuringVSDevice complexity

Solution Approach 1:

The patent employs positron-emitting radioligands with specific decay parameters and binding affinity characteristics to optimize imaging performance. By selecting and optimizing radiotracer parameters (half-life, binding affinity, specificity), the patent achieves effective MGL detection while managing synthesis complexity through parameter optimization rather than simplifying the fundamental radioligand requirements

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The radioligand serves as an intermediary molecule that bridges the detection system (PET scanner) and the target (MGL enzyme). This intermediary enables indirect detection of MGL expression and distribution through positron emission, transforming an otherwise difficult-to-measure biological parameter into detectable radiation signals

Inventive Principle:

Principle #24Intermediary (Mediator)

2Measurement precision

If a selective MGL-affinity compound with positron-emitting radioligand is used, then measurement precision of MGL receptor expression is improved, but the ease of manufacture decreases

Engineering Contradiction:

ImproveMGL receptor expression quantificationVSAvoidradiolabelled compound production

Core Design Contradiction:

Measurement precisionVSEase of manufacture

Solution Approach 1:

The patent uses pre-synthesized non-radioactive precursor compounds with established chemical structures and proven MGL affinity. These precursors are prepared in advance through conventional organic synthesis, and only require final radiolabeling steps. This preliminary preparation of stable precursors simplifies the overall manufacturing process while maintaining measurement precision

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The radioactive component is extracted as a separate element that can be introduced into pre-synthesized molecular frameworks. This separation allows the complex selective binding portion of the molecule to be developed and optimized independently through conventional chemistry, while the radiolabeling step is handled separately, thus improving measurement precision without entirely sacrificing manufacturability

Inventive Principle:

Principle #2Taking out (Extraction)

3Adaptability or versatility

If radiolabelled MGL ligands are developed for PET imaging, then diagnostic capability for MGL-associated diseases is improved, but the loss of time in radiotracer development and validation increases

Engineering Contradiction:

Improvediagnostic application for MGL-related disordersVSAvoidradiotracer development and validation period

Core Design Contradiction:

Adaptability or versatilityVSLoss of time

Solution Approach 1:

The patent develops radioligands based on selective MGL-affinity compounds that can be applied across multiple diagnostic indications involving MGL dysregulation (neurodegenerative diseases, psychiatric disorders, cancer). This multi-functional approach allows a single radiotracer platform to serve diverse diagnostic needs, reducing overall development time compared to creating separate tracers for each indication

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent performs preliminary in vitro and in vivo validation studies to establish the pharmacokinetic, binding, and safety profiles of radioligands before clinical deployment. This advance characterization creates a validated platform that can be more rapidly adapted to specific diagnostic applications, reducing the time required for subsequent diagnostic development and approval processes

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20250360234A1Radiolabelled MGL pet ligands

Publication Date: 2025.11.27 JANSSEN PHARMA NV

AI summary

The present invention relates to novel, selective, radiolabeled compound having monoacylglycerol lipase (MGL) affinity which are useful for imaging and quantifying MGL receptor expression, distribution and enzyme occupancy in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.